Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update
Kezar Life Sciences (Nasdaq: KZR) announced key clinical development updates for its zetomipzomib trials. The PORTOLA Phase 2a trial in autoimmune hepatitis (AIH) will continue without modification following a positive safety review by the Independent Data Monitoring Committee (IDMC). Topline data is expected in the first half of 2025. However, the company has decided to discontinue the PALIZADE Phase 2b trial in lupus nephritis (LN) patients after it was placed on clinical hold due to four Grade 5 (fatal) serious adverse events. Kezar will now focus its resources on developing zetomipzomib for AIH. The company's unaudited cash position is approximately $148 million as of September 30, 2024.
- PORTOLA Phase 2a trial in autoimmune hepatitis (AIH) continues without modification after positive IDMC safety review
- No Grade 4 or 5 serious adverse events observed in the PORTOLA trial
- Focusing resources on clinical development of zetomipzomib in AIH, a rare disease with significant unmet medical need
- Strong cash position of approximately $148 million as of September 30, 2024
- Discontinuation of PALIZADE Phase 2b trial in lupus nephritis patients
- PALIZADE trial placed on clinical hold due to four Grade 5 (fatal) serious adverse events
- Delay in potential development of zetomipzomib for lupus nephritis treatment
Insights
The PORTOLA Phase 2a trial for zetomipzomib in autoimmune hepatitis (AIH) continues without modification, following a positive safety review by the Independent Data Monitoring Committee (IDMC). This is encouraging news for Kezar Life Sciences, as it suggests the drug's safety profile in AIH remains favorable. The trial's completion of enrollment and expected topline data in H1 2025 provide a clear timeline for potential progress.
However, the discontinuation of the PALIZADE Phase 2b trial in lupus nephritis (LN) due to safety concerns is a significant setback. The occurrence of four Grade 5 (fatal) serious adverse events, including one in the placebo group, raises questions about the drug's safety profile in LN or potential regional factors in the Philippines and Argentina. This decision will likely impact Kezar's pipeline and market potential, as LN represents a larger patient population than AIH.
The company's strategic pivot to focus on AIH, a rare disease with high unmet need, could be a prudent move to maximize resources and extend cash runway. With
Kezar's decision to discontinue the PALIZADE trial in lupus nephritis (LN) and focus on autoimmune hepatitis (AIH) has significant financial implications. While this narrows the company's pipeline, it also extends the cash runway, which stood at approximately
However, the loss of the LN program likely reduces Kezar's total addressable market and potential future revenue streams. AIH, being a rare disease, represents a smaller market opportunity compared to LN. This could impact long-term valuation projections and investor sentiment. The company's ability to successfully advance zetomipzomib in AIH becomes important for maintaining investor confidence and supporting the stock price.
The continuation of the PORTOLA trial without modification is a positive sign, potentially de-risking the AIH program to some extent. Investors should watch for the topline data expected in H1 2025, as positive results could significantly boost Kezar's valuation. Conversely, any safety concerns arising from the full investigation of PALIZADE could pose risks to the entire zetomipzomib program and Kezar's market position.
-
PORTOLA Phase 2a clinical trial in patients with autoimmune hepatitis (AIH) to continue without modification following review by Independent Data Monitoring Committee (IDMC); reiterating guidance of topline data in first half 2025 - PALIZADE Phase 2b clinical trial in patients with active lupus nephritis (LN) will be discontinued; focusing resources on clinical development of zetomipzomib in AIH
The IDMC overseeing the
Kezar has also made the strategic decision to terminate the PALIZADE Phase 2b clinical trial in patients with active LN and focus clinical development efforts of zetomipzomib in AIH, a rare disease with a significant unmet medical need. PALIZADE was recently placed on clinical hold following the recommendation of the IDMC after its assessment of four Grade 5 (fatal) SAEs that occurred in patients enrolled in
“The IDMC recommendation to continue the
Kezar’s unaudited cash position is approximately
About
About Autoimmune Hepatitis
Autoimmune hepatitis (AIH) is a rare chronic disease in which the immune system attacks the liver and causes inflammation and tissue damage, severely impacting patients’ physical health and quality of life. Lifelong maintenance therapy is required to avoid relapse and burdensome adverse effects. If left untreated, AIH can lead to cirrhosis, liver failure and hepatocellular carcinoma. In
About Kezar Life Sciences
Kezar Life Sciences is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases. For more information, visit www.kezarlifesciences.com, and follow us on LinkedIn, Facebook, Twitter and Instagram.
Cautionary Note on Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “can,” “should,” “expect,” “believe,” “plans,” “potential,” “anticipate” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Kezar’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Kezar’s future results or performance to differ materially from those expressed or implied by the forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the nature, frequency and severity of adverse events; the design, progress and outcome of Kezar’s clinical trials; Kezar’s ability to report data from its clinical trials on expected timelines, if at all; and Kezar’s ability to extend its cash runway. Many factors may cause differences between current expectations and actual results, including those factors that are discussed in Kezar’s filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20241017004238/en/
Investor and Media Contact:
Gitanjali Jain
Senior Vice President, Investor Relations and External Affairs
Kezar Life Sciences, Inc.
gjain@kezarbio.com
Source: Kezar Life Sciences, Inc.
FAQ
What is the status of Kezar Life Sciences' PORTOLA trial for zetomipzomib in autoimmune hepatitis?
Why did Kezar Life Sciences (KZR) discontinue the PALIZADE trial for lupus nephritis?
What is Kezar Life Sciences' (KZR) cash position as of September 30, 2024?